Dr. Ravi Vij MD Medical Oncologist

Dr. Ravi Vij is a medical oncologist in Saint Louis, Missouri and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Missouri Baptist Medical Center. He received his medical degree from Maulana Azad Medical College and has been in practice for 23 years. Dr. Vij accepts several types of health insurance, listed below. He is one of 39 doctors at Barnes-Jewish Hospital and one of 6 at Missouri Baptist Medical Center who specialize in Medical Oncology. He also speaks multiple languages, including Hindi/Urdu.

Are you Dr. Vij? Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: Hematologic

Clinical Interests: Transplants, Stem cell, HEMATOLOGIC MALIGNANCIES, STEM CELL TRANSPLANTATION

Hospital Affiliation

Barnes-Jewish Hospital
Ranked #21 in Cancer

Missouri Baptist Medical Center

Education & Medical Training

Rush Medical College of Rush University
Residency, Internal Medicine, 1996

Washington University
Fellowship, Hematology/Oncology, 1999

Maulana Azad Medical College
Class of 1990

Certifications & Licensure

American Board of Internal Medicine
Certified 18 years in Internal Medicine

American Board of Internal Medicine
Certified 15 years in Medical Oncology

American Board of Internal Medicine
Certified 14 years in Hematology

MO State Medical License
Active through 2015

Publications & Presentations

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes.
Bhamidipati, P. K.,DiPersio, J. F.,Stokerl-Goldstein, K.,Rashidi, A.,Gao, F.,Uy, G. L.,Westervelt, P.,Vij, R.,Schroeder, M. A.,Abboud, C. N.,Keller, J. W.,Fehniger, T. A.,Romee, R.

Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome (MDS): CALGB 10105 (Alliance).
Wang, X.,Owzar, K.,Gupta, P.,Larson, R. A.,Mulkey, F.,Miller, A. A.,Lewis, L. D.,Hurd, D.,Vij, R.,Ratain, M. J.,Murry, D. J.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Azab, F.,Vali, S.,Abraham, J.,Potter, N.,Muz, B.,de la Puente, P.,Fiala, M.,Paasch, J.,Sultana, Z.,Tyagi, A.,Abbasi, T.,Vij, R.,Azab, A. K.

See all 62 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Anthem Blue Access PPO
  • CIGNA Open Access
  • CIGNA PPO
  • Coventry Health Care PPO Platinum
  • Coventry Oklahoma
  • First Health PPO
  • Great West PPO
  • Multiplan PHCS PPO
  • United Healthcare - Direct Options PPO
  • Anthem Blue Access Choice PPO
  • BCBS Blue Card PPO
  • BCBS Illinois PPO
  • BCBS Oklahoma BlueChoice
  • CIGNA HMO
  • Coventry Missouri - HMO/POS
  • HealthLink PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support


See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Medical Oncologists

See all Medical Oncologists near St. Louis, MO See all Medical Oncologists in Missouri

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.